|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
2
|
Sree SV, Ng EY, Acharya RU and Faust O:
Breast imaging: A survey. World J Clin Oncol. 2:171–178. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wekking D, Porcu M, De Silva P, Saba L,
Scartozzi M and Solinas C: Breast MRI: clinical indications,
recommendations, and future applications in breast cancer
diagnosis. Curr Oncol Rep. 25:257–267. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gargiulo M, Dien E, Gal J, Schiappa R,
Elkind L and Lamarque M: Predictive factors for non-mass
enhancement occult in conventional breast imaging: The ‘PAMAS’
study. Eur J Radiol. 184:1119622025. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mohamed S, Elhamd EA and Attia NM:
Non-mass enhancement on breast MRI: Clues to a more confident
diagnosis. Egypt J Radiol Nucl Med. 55:872024. View Article : Google Scholar
|
|
6
|
Spak DA, Plaxco JS, Santiago L, Dryden MJ
and Dogan BE: BI-RADS® fifth edition: A summary of
changes. Diagn Interv Imaging. 98:179–190. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cheng L, Bai Y, Zhang J, Liu M, Li X,
Zhang A, Zhang X and Ma L: Optimization of apparent diffusion
coefficient measured by diffusion-weighted MRI for diagnosis of
breast lesions presenting as mass and non-mass-like enhancement.
Tumour Biol. 34:1537–1545. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang QX, Ji X, Feng LL, Zheng L, Zhou XQ,
Wu Q and Chen X: Significant MRI indicators of malignancy for
breast non-mass enhancement. J Xray Sci Technol. 25:1033–1044.
2017.PubMed/NCBI
|
|
9
|
Liu G, Li Y, Chen SL and Chen Q: Non-mass
enhancement breast lesions: MRI findings and associations with
malignancy. Ann Transl Med. 10:3572022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Aydin H: The MRI characteristics of
non-mass enhancement lesions of the breast: Associations with
malignancy. Br J Radiol. 92:201804642019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou J, Li M, Liu D, Sheng F and Cai J:
Differential diagnosis of benign and malignant breast papillary
neoplasms on MRI with non-mass enhancement. Acad Radiol. 30 (Suppl
2):S127–S32. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
D'Orsi C, Sickles E, Mendelson E and
Morris EA: ACR BI-RADS Atlas: Breast Imaging Reporting and Data
System. American College of Radiology; Reston, VA: 2013
|
|
13
|
Cheng L and Li X: Breast magnetic
resonance imaging: Kinetic curve assessment. Gland Surg. 2:50–53.
2013.PubMed/NCBI
|
|
14
|
Asada T, Yamada T, Kanemaki Y, Fujiwara K,
Okamoto S and Nakajima Y: Grading system to categorize breast MRI
using BI-RADS 5th edition: A statistical study of non-mass
enhancement descriptors in terms of probability of malignancy. Jpn
J Radiol. 36:200–208. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yoon GY, Choi WJ, Cha JH, Shin HJ, Chae EY
and Kim HH: The role of MRI and clinicopathologic features in
predicting the invasive component of biopsy-confirmed ductal
carcinoma in situ. BMC Med Imaging. 20:952020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bluemke DA, Gatsonis CA, Chen MH,
DeAngelis GA, DeBruhl N, Harms S, Heywang-Köbrunner SH, Hylton N,
Kuhl CK, Lehman C, et al: Magnetic resonance imaging of the breast
prior to biopsy. JAMA. 292:2735–2742. 2004. View Article : Google Scholar : PubMed/NCBI
|
